复方脑肽节苷脂注射液对重症颅脑损伤患者治疗效果及对预后的影响

Curative Effect of Compound Cerebral peptide Glycoside in the Treatment of Patients with Severe Craniocerebral Injurty and Effect on Prognosis

目的:探讨复方脑肽节苷脂注射液对重症颅脑损伤患者血清神经肽Y(NPY)、星形胶质源性蛋白(S100β)、降钙素基因相关肽(GFAP)水平及预后的影响.方法:选取2015年4月—2018年8月我院收治的重症颅脑损伤患者104例,按随机数字表法分为试验组和对照组,各52例.对照组予以常规治疗,试验组在常规治疗基础上予以复方脑肽节苷脂注射液(10 mL+250 mL氯化钠注射液,静注,qd)治疗,均治疗4周.比较两组治疗前、治疗4周后昏迷程度评分(GCS)、神经功能缺损程度评分(NIHSS)、认知功能评分(MMSE)、生活质量评分(SF-36)、血清神经损伤有关指标(NPY、S100β、GFAP)水平,治疗后随访3个月比较两组格拉斯哥预后评分量表(GOS)预后分级情况.结果:治疗4周后两组GCS评分较治疗前提高,且试验组高于对照组,NIHSS评分较治疗前降低,且试验组低于对照组,差异有统计学意义(P<0.05);治疗4周后两组MMSE、SF-36评分较治疗前提高,且试验组高于对照组,差异有统计学意义(P<0.05);治疗4周后两组血清NPY、S100β、GFAP水平较治疗前降低,且试验组低于对照组,差异有统计学意义(P<0.05);治疗后3个月试验组GOS预后分级情况较对照组良好,差异有统计学意义(P<0.05).结论:复方脑肽节苷脂注射液治疗重症颅脑损伤可降低昏迷与神经功能损伤程度,改善患者认知功能、生活质量及GOS预后分级情况.

Objective:To investigate the effect of compound cerebral glycoside injection on serum neuropeptide Y(NPY),astrocyte-derived protein(S100β)and calcitonin gene-related peptide(GFAP)in patients with severe craniocerebral injury and the prognosis of the disease.Methods:104 patients with severe craniocerebral injury admitted to our hospital from April 2015 to August 2018 were selected and randomly divided into an experimental group and a control group,52 cases each.The patients in the control group received conventional treatment,and the patients in the experimental group were treated with compound cerebral peptide glycoside injection(10 mL+250 mL sodium chloride injection,intravenous injection,qd)on the basis of the conventional treatment.All patients were treated for 4 weeks.The Glasgow coma scores(GCS),the scores of the National Institute of Health Stroke Scale(NIHSS),the scor es of mini-mental state examination(MMSE),the scores of quality of life(SF-36),the levels of serum nerve injury-related indexes(NPY,S100β,GFAP)before treatment and after 4 weeks of treatment were compared between the two groups.The patients were followed up for 3 months after treatment,and the prognosis grading of the Glasgow outcome scale(GOS)were compared between the two groups.Results:The GCS after 4 weeks of treatment were higher than those before treatment in the two groups and the scores in the experimental group were higher than those in the control group,while the scores of NIHSS were lower than those before treatment and the scores in the experimental group were lower than those in the control group,with statistically significant differences(P<0.05).The scores of MMSE and SF-36 after 4 weeks of treatment were higher than those before treatment in the two groups,and the scores in the experimental group were higher than those in the control group,with statistically significant differences(P<0.05).The serum levels of NPY,S100βand GFAP after 4 weeks of treatment were lower than those before treatment in the two groups,and the levels in the experimental group were lower than those in the control group,with statistically significant differences(P<0.05).The prognosis grading of GOS after 3 months of treatment in the experimental group was better than that in the control group,with statistically significant difference(P<0.05).Conclusion:Cerebral peptide grycoside injection can reduce the degree of coma and neurological injury and improve the cognitive function and the quality of life of the patients and the prognosis grading of GOS.